EMA/790731/2022

European Medicines Agency decision

P/0464/2022

of 28 October 2022

on the agreement of a paediatric investigation plan for beremagene geperpavec (EMEA-002472-PIP03-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0464/2022

of 28 October 2022

on the agreement of a paediatric investigation plan for beremagene geperpavec (EMEA-002472-PIP03-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Krystal Biotech, Inc. on 24 January 2022 under Article 16(1) of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 September 2022, in accordance with Article 17 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for beremagene geperpavec, gel, topical use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

This decision is addressed to Krystal Biotech, Inc., 2100 Wharton Street, Suite 701, 15203 - Pittsburgh, PA, United States.

EMA/PDCO/579227/2022
Amsterdam, 9 September 2022

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan

EMEA-002472-PIP03-22

Scope of the application

Active substance(s):

Beremagene geperpavec

Condition(s):

Treatment of dystrophic epidermolysis bullosa

Pharmaceutical form(s):

Gel

Route(s) of administration:

Topical use

Name/corporate name of the PIP applicant:

Krystal Biotech, Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Krystal Biotech, Inc. submitted for agreement to the European Medicines Agency on 24 January 2022 an application for a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 21 February 2022.

Supplementary information was provided by the applicant on 30 May 2022. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of dystrophic epidermolysis bullosa

2.1.1. Indication(s) targeted by the PIP

Treatment of dystrophic epidermolysis bullosa from birth to adults

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Gel

2.1.4. Measures

Area	**Description**
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	**Study 1** Open-label, randomised, placebo-controlled trial to evaluate efficacy and safety of beremagene geperpavec in children from birth to less than 18 years of age with dystrophic epidermolysis bullosa (KB103-001, GEM-1) **Study 2** Double blind, randomised, placebo-controlled trial to evaluate efficacy and safety of beremagene geperpavec in children from birth to less than 18 years of age with dystrophic epidermolysis bullosa (B-VEC-03, GEM-3) **Study 3** Open-label, uncontrolled trial to evaluate safety of beremagene geperpavec in children from birth to less than 18 years of age who participated in Study 2 and in newly diagnosed patients with dystrophic epidermolysis bullosa (B-VEC-EX02)
Extrapolation, modelling and simulation studies	Not applicable

Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2022
Deferral for one or more measures contained in the paediatric investigation plan:	No